{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:11:37Z","timestamp":1780625497720,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10072-021-05261-8","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T01:02:44Z","timestamp":1619139764000},"page":"517-523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Our reasons for converting to valproic acid treatment in female patients with genetic generalized epilepsy: a retrospective, single-centre study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-9450","authenticated-orcid":false,"given":"Dilara","family":"Mermi Dibek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130brahim","family":"\u00d6ztura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bar\u0131\u015f","family":"Baklan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"5261_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2165\/00003495-199447020-00008","volume":"47","author":"R Davis","year":"1994","unstructured":"Davis R, Peters DH, McTavish D (1994) Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 47:332\u2013372","journal-title":"Drugs."},{"issue":"3","key":"5261_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eplepsyres.2005.06.001","volume":"65","author":"K Eriksson","year":"2005","unstructured":"Eriksson K, Viinikainen K, M\u00f6nkk\u00f6nen A, \u00c4iki\u00e4 M, Nieminen P, Heinonen S, K\u00e4lvi\u00e4inen R (2005) Children exposed to valproate in utero: population-based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 65(3):189\u2013200","journal-title":"Epilepsy Res"},{"issue":"7","key":"5261_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","volume":"10","author":"T Tomson","year":"2011","unstructured":"Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F, EURAP study group (2011) Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10(7):609\u2013617","journal-title":"Lancet Neurol"},{"key":"5261_CR4","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","volume":"360","author":"KJ Meador","year":"2009","unstructured":"Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group (2009) Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360:1597\u20131605","journal-title":"N Engl J Med"},{"issue":"3","key":"5261_CR5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","volume":"12","author":"KJ Meador","year":"2013","unstructured":"Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group (2013) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12(3):244\u2013252. https:\/\/doi.org\/10.1016\/S1474-4422(12)70323-X","journal-title":"Lancet Neurol"},{"issue":"4","key":"5261_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1212\/WNL.0000000000001182","volume":"84","author":"GA Baker","year":"2015","unstructured":"Baker GA, Bromley RL, Briggs M, Cheyne CP, Cohen MJ, Garcia-Finana M, Gummery A, Kneen R, Loring DW, Mawer G, Meador KJ, Shallcross R, Clayton-Smith J, On behalf of the Liverpool and Manchester Neurodevelopment Group (2015) IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 84(4):382\u2013390","journal-title":"Neurology"},{"issue":"4","key":"5261_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1212\/WNL.0b013e3182088297","volume":"76","author":"R Shallcross","year":"2011","unstructured":"Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA, Liverpool Manchester Neurodevelopment Group, UK Epilepsy and Pregnancy Register (2011) Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 76(4):383\u2013389","journal-title":"Neurology"},{"issue":"3","key":"5261_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1212\/WNL.0000000000000030","volume":"82","author":"R Shallcross","year":"2014","unstructured":"Shallcross R, Bromley RL, Cheyne CP, Garcia-Finana M, Irwin B, Morrow J et al (2014) In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. Neurology 82(3):213\u2013221","journal-title":"Neurology"},{"key":"5261_CR9","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jama.2013.2270","volume":"309","author":"J Christensen","year":"2013","unstructured":"Christensen J, Gronborg TK, Sorensen MJ et al (2013) Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 309:1696\u20131703","journal-title":"JAMA."},{"key":"5261_CR10","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1212\/WNL.0000000000003157","volume":"87","author":"RL Bromley","year":"2016","unstructured":"Bromley RL, Calderbank R, Cheyne CP, Rooney C, Trayner P, Clayton-Smith J, Garc\u00eda-Fi\u00f1ana M, Irwin B, Morrow JI, Shallcross R, Baker GA, UK Epilepsy and Pregnancy Register (2016) Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology 87:1943\u20131953","journal-title":"Neurology"},{"issue":"3","key":"5261_CR11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.reprotox.2012.05.038","volume":"34","author":"T Rihtman","year":"2012","unstructured":"Rihtman T, Parush S, Ornoy A (2012) Preliminary findings of the developmental effects of in utero exposure to topiramate. Reprod Toxicol 34(3):308\u2013311","journal-title":"Reprod Toxicol"},{"key":"5261_CR12","doi-asserted-by":"crossref","unstructured":"IE Scheffer et al ILAE Classification of the Epilepsies Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58(4): 512-521).","DOI":"10.1111\/epi.13709"},{"key":"5261_CR13","unstructured":"Epilepsies: diagnosis and management Clinical guideline [CG137] Published date: 11 January 2012 Last updated: 11 February 2020."},{"issue":"1","key":"5261_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.clinph.2015.05.031","volume":"127","author":"U Seneviratne","year":"2016","unstructured":"Seneviratne U, Hepworth G, Cook M, D'Souza W (2016) Atypical EEG abnormalities in genetic generalized epilepsies. Clin Neurophysiol 127(1):214\u2013220","journal-title":"Clin Neurophysiol"},{"key":"5261_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yebeh.2019.06.031","volume":"98","author":"M Bosak","year":"2019","unstructured":"Bosak M, S\u0142owik A, Turaj W (2019) Why do some women with epilepsy use valproic acid despite current guidelines? A single-center cohort study. Epilepsy Behav 98:1\u20135","journal-title":"Epilepsy Behav"},{"key":"5261_CR16","first-page":"CD003032","volume":"4","author":"EB Posner","year":"2005","unstructured":"Posner EB, Mohamed K, Marson AG (2005) Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 4:CD003032","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"5261_CR17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/archneur.60.8.1100","volume":"60","author":"A Prasad","year":"2003","unstructured":"Prasad A, Kuzniecky RI, Knowlton RC, Welty TE, Martin RC, Mendez M, Faught RE (2003) Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 60(8):1100\u20131105","journal-title":"Arch Neurol"},{"issue":"3","key":"5261_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s11096-018-0641-9","volume":"40","author":"MS de Almeida Campos","year":"2018","unstructured":"de Almeida Campos MS et al (2018) Comparative efficacy of antiepileptic drugs for patients with generalized epileptic seizures: systematic review and network meta-analyses. Int J Clin Pharm 40(3):589\u2013598","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"5261_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1528-1167.2007.01524.x","volume":"49","author":"P Striano","year":"2008","unstructured":"Striano P, Sofia V, Capovilla G, Rubboli G, di Bonaventura C, Coppola A, Vitale G, Fontanillas L, Giallonardo AT, Biondi R, Romeo A, Viri M, Zara F, Striano S (2008) A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). Epilepsia. 49(3):425\u2013430","journal-title":"Epilepsia."},{"issue":"3","key":"5261_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/08830738050200030801","volume":"20","author":"HL Kim","year":"2005","unstructured":"Kim HL, Aldridge J, Rho JM (2005) Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J Child Neurol 20(3):212\u2013219","journal-title":"J Child Neurol"},{"issue":"18","key":"5261_CR21","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","volume":"69","author":"SF Berkovic","year":"2007","unstructured":"Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U, On behalf of the Levetiracetam N01057 Study Group (2007) On behalf of the Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology. 69(18):1751\u20131760","journal-title":"Neurology."},{"issue":"8","key":"5261_CR22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","volume":"70","author":"S Noachtar","year":"2008","unstructured":"Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J, For the N166 Levetiracetam Study Group (2008) Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology. 70(8):607\u2013616","journal-title":"Neurology."},{"issue":"1","key":"5261_CR23","first-page":"75","volume":"75","author":"A Nicolson","year":"2004","unstructured":"Nicolson A, Appleton RE, Chadwick DW, Smith DF (2004) The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalized epilepsies. J Neurol Neurosurg Psychiatry 75(1):75\u201379","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"5261_CR24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1684\/j.1950-6945.2004.tb00075.x","volume":"6","author":"SV Kothare","year":"2004","unstructured":"Kothare SV, Valencia I, Khurana DS, Hardison H, Melvin JJ, Legido A (2004) Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 6(4):267\u2013270","journal-title":"Epileptic Disord"},{"issue":"4","key":"5261_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.yebeh.2004.04.002","volume":"5","author":"GL Morris","year":"2004","unstructured":"Morris GL, Hammer AE, Kustra RP, Messenheimer JA (2004) Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav 5(4):509\u2013512","journal-title":"Epilepsy Behav"},{"issue":"10","key":"5261_CR26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1136\/jnnp-2020-323524","volume":"91","author":"DG Vossler","year":"2020","unstructured":"Vossler DG, Knake S, O'Brien TJ, Watanabe M, Brock M, Steiniger-Brach B, Williams P, Roebling R, SP0982 co-investigators (2020) Efficacy and safety of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures: a double-blind, randomized, placebo-controlled trial. J Neurol Neurosurg Psychiatry 91(10):1067\u20131075","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5261_CR27","first-page":"1","volume":"00","author":"E Cerulli Irelli","year":"2019","unstructured":"Cerulli Irelli E, Morano A, Cocchi E et al (2019) Doing without valproate in women of childbearing potential with Idiopathic generalized epilepsy: Implications on seizure outcome. Epilepsia. 00:1\u20138","journal-title":"Epilepsia."},{"key":"5261_CR28","doi-asserted-by":"crossref","unstructured":"Gesche J et al (2020) Patterns and prognostic markers for treatment response in generalized epilepsies. Neurology:95\/18","DOI":"10.1212\/WNL.0000000000010644"},{"key":"5261_CR29","doi-asserted-by":"publisher","first-page":"116940","DOI":"10.1016\/j.jns.2020.116940","volume":"415","author":"E Cerulli Irelli","year":"2020","unstructured":"Cerulli Irelli E, Cocchi E, Morano A, Casciato S, Fanella M, Albini M, Fisco G, Barone FA, Orlando B, Mascia A, Manfredi M, Fattouch J, Giallonardo AT, di Gennaro G, di Bonaventura C (2020) Valproate impact and sex-dependent seizure remission in patients with idiopathic generalized epilepsy. J Neurol Sci 415:116940","journal-title":"J Neurol Sci"},{"issue":"7","key":"5261_CR30","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/epi.13021","volume":"56","author":"T Tomson","year":"2015","unstructured":"Tomson T, Marson A, Boon P, Canevini MP, Covanis A, Gaily E, K\u00e4lvi\u00e4inen R, Trinka E (2015) Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 56(7):1006\u20131019. https:\/\/doi.org\/10.1111\/epi.13021","journal-title":"Epilepsia."},{"key":"5261_CR31","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/ane.13231","volume":"141","author":"H Angus-Leppan","year":"2020","unstructured":"Angus-Leppan H, Moghim MM, Cock H, Kinton L, Wells MS, Shankar R (2020) Valproate risk form\u2014Surveying 215 clinicians involving 4775 encounters. Acta Neurol Scand 141:483\u2013490","journal-title":"Acta Neurol Scand"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05261-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05261-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05261-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T04:47:10Z","timestamp":1724906830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05261-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5261"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05261-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"11 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval of Dokuz Eylul University\u00a0(No.: 2020 \/ 17-25) was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that there are no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}